Omeros Corporation (OMER) Holdings Cut by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC trimmed its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 14.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,000 shares of the biopharmaceutical company’s stock after selling 4,000 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.05% of Omeros Corporation worth $478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Omeros Corporation by 5.1% in the 1st quarter. Vanguard Group Inc. now owns 1,731,391 shares of the biopharmaceutical company’s stock valued at $26,179,000 after purchasing an additional 83,868 shares during the last quarter. Capital Analysts LLC lifted its holdings in shares of Omeros Corporation by 5,895.0% in the 2nd quarter. Capital Analysts LLC now owns 59,950 shares of the biopharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 58,950 shares during the last quarter. Ingalls & Snyder LLC lifted its holdings in shares of Omeros Corporation by 1.0% in the 2nd quarter. Ingalls & Snyder LLC now owns 5,143,289 shares of the biopharmaceutical company’s stock valued at $102,377,000 after purchasing an additional 50,970 shares during the last quarter. Chicago Equity Partners LLC purchased a new stake in shares of Omeros Corporation in the 1st quarter valued at about $639,000. Finally, Morgan Stanley lifted its holdings in shares of Omeros Corporation by 20.1% in the 1st quarter. Morgan Stanley now owns 199,087 shares of the biopharmaceutical company’s stock valued at $3,010,000 after purchasing an additional 33,285 shares during the last quarter. 44.93% of the stock is owned by institutional investors.

In other Omeros Corporation news, VP Michael A. Jacobsen sold 12,000 shares of the firm’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $24.95, for a total value of $299,400.00. Following the transaction, the vice president now owns 19,500 shares of the company’s stock, valued at $486,525. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael A. Jacobsen sold 24,000 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now directly owns 2,650 shares in the company, valued at approximately $56,180. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

Shares of Omeros Corporation (NASDAQ:OMER) opened at 21.04 on Friday. The firm’s 50-day moving average price is $21.62 and its 200 day moving average price is $17.66. Omeros Corporation has a 1-year low of $7.20 and a 1-year high of $27.09. The stock’s market capitalization is $942.66 million.

Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.12. The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $14.63 million. The firm’s revenue for the quarter was up 71.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.32) earnings per share. Analysts expect that Omeros Corporation will post ($1.30) EPS for the current fiscal year.

Several analysts have recently weighed in on the company. BidaskClub downgraded Omeros Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, June 28th. Maxim Group set a $23.00 target price on Omeros Corporation and gave the company a “buy” rating in a report on Monday, May 22nd. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Omeros Corporation in a report on Wednesday, June 14th. Cantor Fitzgerald set a $15.00 target price on Omeros Corporation and gave the company a “hold” rating in a report on Tuesday, June 13th. Finally, ValuEngine raised Omeros Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $33.38.

ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/09/10/omeros-corporation-omer-holdings-cut-by-sheaff-brock-investment-advisors-llc.html.

Omeros Corporation Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply